Krystal Biotech Inc (NASDAQ:KRYS) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 1,011,200 shares, an increase of 20.5% from the June 30th total of 839,200 shares. Currently, 12.8% of the company’s stock are short sold. Based on an average daily trading volume, of 221,800 shares, the short-interest ratio is currently 4.6 days.

A number of hedge funds have recently added to or reduced their stakes in KRYS. BlackRock Inc. boosted its position in Krystal Biotech by 989.8% during the second quarter. BlackRock Inc. now owns 601,514 shares of the company’s stock worth $24,224,000 after purchasing an additional 546,317 shares during the period. Citadel Advisors LLC boosted its position in shares of Krystal Biotech by 54.0% in the second quarter. Citadel Advisors LLC now owns 497,170 shares of the company’s stock valued at $20,021,000 after acquiring an additional 174,296 shares during the period. Vanguard Group Inc. boosted its position in shares of Krystal Biotech by 40.6% in the second quarter. Vanguard Group Inc. now owns 496,879 shares of the company’s stock valued at $20,009,000 after acquiring an additional 143,409 shares during the period. Garnet Equity Capital Holdings Inc. bought a new stake in shares of Krystal Biotech in the second quarter valued at about $1,812,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Krystal Biotech by 210.2% in the second quarter. Bank of New York Mellon Corp now owns 64,726 shares of the company’s stock valued at $2,606,000 after acquiring an additional 43,859 shares during the period. 38.59% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently weighed in on KRYS shares. Zacks Investment Research downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. Guggenheim boosted their target price on shares of Krystal Biotech from $48.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Chardan Capital boosted their target price on shares of Krystal Biotech from $57.50 to $75.00 and gave the stock a “buy” rating in a report on Monday, June 24th. BidaskClub upgraded shares of Krystal Biotech from a “hold” rating to a “buy” rating in a report on Wednesday, July 3rd. Finally, William Blair restated a “buy” rating on shares of Krystal Biotech in a report on Monday, June 24th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $59.20.

KRYS stock traded down $0.69 during midday trading on Wednesday, reaching $41.80. 115,600 shares of the company were exchanged, compared to its average volume of 136,867. The company has a debt-to-equity ratio of 0.01, a current ratio of 49.80 and a quick ratio of 49.80. The stock’s 50-day simple moving average is $45.39. Krystal Biotech has a one year low of $14.30 and a one year high of $51.67. The firm has a market capitalization of $735.08 million, a price-to-earnings ratio of -43.09 and a beta of 0.99.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.05). On average, research analysts expect that Krystal Biotech will post -1.47 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in Phase II of a Phase I/II clinical study to treat dystrophic epidermolysis bullosa, a genetic disease.

Further Reading: What is dollar cost averaging (DCA)?

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.